The European Association for Clinical Pharmacology and Therapeutics (EACPT) Young Clinical Pharmacologists Working Group has been working on a research project with the objective to assess the perception of healthcare professionals from all over Europe on medical cannabis and other cannabis-based products. Previous studies have investigated this question; however, it has not yet been assessed in the European countries despite the current changes towards cannabis regulation. To this end, a survey questionnaire has been prepared that targets all health professionals who are likely to be involved in the prescription, dispensing, and administration of these products, or even in giving advice on them.

Information about the survey

We are health professionals and researchers of the European Association for Clinical Pharmacology and Therapeutics (EACPT). With this survey, we would like to improve the understanding of the knowledge and attitudes of experienced health professionals towards medical cannabis across Europe. The results of this research study will be published in a scientific journal. This questionnaire is not purposed for commercial use.

Definitions

**Cannabis-based products** correspond to formulations prepared from raw parts of the Cannabis sativa plant or obtained from cannabinoids. These latter can be natural (i.e., extracted from the plant) or synthetised.

**Medical cannabis** refers to use of Cannabis sativa prescribed, delivered, administered or advised by authorised professionals to treat a medical condition in the concerned patients. The concerned products include raw cannabis and any cannabis magistral or standardised preparations made from raw parts of the Cannabis sativa plant or obtained after extraction.

**Medicinal cannabis products** refer to plant-derived and synthetic cannabinoid-containing products with a marketing authorisation.

**Recreational cannabis** refers to use of cannabis-based products (including natural or synthetic cannabinoids classified as narcotics) in search for psychoactive effects.

Instructions

- Your participation in this survey is voluntary: you are free to choose whether to participate or not. Agreement to Question 1 (below) confirms your consent to participate.
- You can withdraw or stop your participation at any time.
- You may save your answers as a draft prior to posting and have the questionnaire completed later.
- **This survey is anonymous. The questionnaire collects no identifying data. Consequently, the researchers have no possibility to connect your responses with you as an individual.**
- For each question, please fill in one box (or several boxes when specified), or write in an answer.
- If you come across a question you would rather not answer, please fill in the box “Choosing not to answer (CNTA)” and go on to the next question.
- Any health professional hovering around medical cannabis may participate in this survey, including in countries where medical cannabis is not authorised at the time of the survey. In the latter case, the concerned professionals should answer the present questionnaire by placing themselves in the event that medical cannabis was authorised.
- Undergraduate students may not participate in this survey.
- The results of this research study will be made available in the form of an article in a scientific journal and under a synthetic version on the Web.

**Ethics**

This project was approved by the Comité d’Evaluation de l’INSERM (CEEL/IRB 00003888) on 09/02/2021. The scientific coordinator is based in France and affiliated with the University of Toulouse. This survey respects the GPDR and the French law on data protection (CNIL, Commission nationale de l’informatique et des libertés, MR-004 reference methodology).

The survey questionnaire may be assessed by clicking on the following link:


For further information about the survey, please contact Emilie Jouanjus (English language) at: +33 561 145 970 or emilie.jouanjus@univ-tlse3.fr